INSPECS Group Full Year 2023 Earnings: EPS Beats Expectations

INSPECS Group (LON:SPEC) Full Year 2023 Results

Key Financial Results

• Revenue: UK£203.3m (down 1.1% from FY 2022).
• Net loss: UK£997.0k (loss narrowed by 85% from FY 2022).
• UK£0.01 loss per share (improved from UK£0.064 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

INSPECS Group EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 77%.

Looking ahead, revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in the United Kingdom.

Performance of the British Medical Equipment industry.

The company's shares are up 3.1% from a week ago.

Risk Analysis

Before you take the next step you should know about the 2 warning signs for INSPECS Group that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.